Quality of Life in Polycystic Ovary Syndrome After Anti-Androgen Therapy Using PCOSQOL-47 and PCOSQOL-42
March 2026
in “
Endocrine Metabolic & Immune Disorders - Drug Targets
”
Studysummary This study found that in women with PCOS, a combination of finasteride and spironolactone significantly improved all health-related quality of life scales and reduced hyperandrogenism within four months, supporting its role alongside lifestyle measures.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on eurekaselect.com →